Nemolizumab in moderate-to-severe atopic dermatitis with inadequate response to cyclosporine A

Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Nemolizumab with Placebo (2 arms). Primary endpoints: Proportion of Participants with Eczema Area and Severity Index-75 at 16 weeks and Proportion of Participants with an Improvement of Peak Pruritus Numeric Rating Scale >= 4 at 16 weeks. Planned start Jan 2023; status: withdrawn.